BELIEVE BIG’s Post

📣Help Believe Big Spread the Word! Enroll in the MD Anderson Pediatric Mistletoe Trial II 🌱 ⭐Study #2022-0877: ISCADER P (MISTLETOE) Immunotherapy Trial ⭐To improve event-free survival in pediatric patients with relapsed osteosarcoma after resection of pulmonary metastases. This Phase II trial is led by Dr. Karen Moody at MD Anderson, with support from Dr. Katy Offer, a pediatric oncologist in New Jersey. Who Can Participate? ✅Ages 8-30 years old ✅Diagnosis of relapsed osteosarcoma ✅Undergone lung resection (surgery) About the Therapy: Participants will receive subcutaneous Iscador P (mistletoe) injections three times a week for 52 weeks. Please share this opportunity with anyone who might qualify. Together, we can advance treatment and provide hope to families. 🔗Learn more & sign up: https://loom.ly/FOlLYjU #MistletoeTherapy #Osteosarcoma #ClinicalTrial #MDAnderson #CancerResearch #HopeForOsteosarcoma #BelieveBig

ISCADOR P (MISTLETOE) immunotherapy to improve event free survival in patients with relapsed osteosarcoma after resection of pulmonary metastases

ISCADOR P (MISTLETOE) immunotherapy to improve event free survival in patients with relapsed osteosarcoma after resection of pulmonary metastases

mdanderson.org

To view or add a comment, sign in

Explore topics